tradingkey.logo


tradingkey.logo


scPharmaceuticals Inc

SCPH
5.670USD
0.0000.00%
終倀 03/27, 16:00ET15分遅れの株䟡
302.16M時䟡総額
損倱額盎近12ヶ月PER


scPharmaceuticals Inc

5.670
0.0000.00%

詳现情報 scPharmaceuticals Inc 䌁業名

scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.

scPharmaceuticals Incの䌁業情報


䌁業コヌドSCPH
䌚瀟名scPharmaceuticals Inc
䞊堎日Nov 17, 2017
最高経営責任者「CEO」Mr. John H. Tucker
埓業員数162
蚌刞皮類Ordinary Share
決算期末Nov 17
本瀟所圚地25 Burlington Mall Road, Suite 203
郜垂BURLINGTON
蚌刞取匕所NASDAQ Global Select Consolidated
囜United States of America
郵䟿番号01803
電話番号16175170730
りェブサむトhttps://www.scpharmaceuticals.com/
䌁業コヌドSCPH
䞊堎日Nov 17, 2017
最高経営責任者「CEO」Mr. John H. Tucker

scPharmaceuticals Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Michael E. Castagna
Mr. Michael E. Castagna
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Prentiss
Mr. Chris Prentiss
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. David Thomson
Mr. David Thomson
Company Secretary, Director
Company Secretary, Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Michael E. Castagna
Mr. Michael E. Castagna
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Prentiss
Mr. Chris Prentiss
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. David Thomson
Mr. David Thomson
Company Secretary, Director
Company Secretary, Director
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sat, Mar 28
曎新時刻: Sat, Mar 28
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Lundbeckfond Invest
5.34%
Tucker (John H)
0.23%
Schaeffer (Leonard D)
0.08%
Nokes (Rachael)
0.06%
Cubist Systematic Strategies, LLC
0.05%
他の
94.25%
株䞻統蚈
株䞻統蚈
比率
Lundbeckfond Invest
5.34%
Tucker (John H)
0.23%
Schaeffer (Leonard D)
0.08%
Nokes (Rachael)
0.06%
Cubist Systematic Strategies, LLC
0.05%
他の
94.25%
皮類
株䞻統蚈
比率
Investment Advisor
5.35%
Individual Investor
0.36%
Hedge Fund
0.05%
Investment Advisor/Hedge Fund
0.01%
他の
94.23%

機関投資家保有株


曎新時刻: Thu, Jan 1
曎新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
224
39.33M
73.28%
-6.50M
2025Q3
203
37.70M
70.24%
-12.04M
2025Q2
207
43.86M
83.06%
-9.87M
2025Q1
220
46.17M
87.73%
-9.39M
2024Q4
216
48.09M
96.18%
-7.84M
2024Q3
205
45.54M
91.15%
-1.25M
2024Q2
187
32.09M
87.10%
-11.64M
2024Q1
180
29.20M
80.96%
-13.79M
2023Q4
174
29.67M
82.49%
-9.34M
2023Q3
165
32.24M
89.90%
-5.09M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Lundbeckfond Invest
2.86M
5.34%
+2.86M
--
Sep 30, 2024
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 3000 ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
iShares Russell 2000 Growth ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
詳现を芋る
Global X Russell 2000 ETF
比率0%
ProShares Hedge Replication ETF
比率0%
Invesco NASDAQ Future Gen 200 ETF
比率0%
iShares Russell 3000 ETF
比率0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0%
iShares Micro-Cap ETF
比率0%
Proshares Ultra Russell 2000
比率0%
ProShares Ultra Nasdaq Biotechnology
比率0%
iShares Russell 2000 Growth ETF
比率0%
Invesco Nasdaq Biotechnology ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™